Tech Company Financing Transactions
Aplagon Funding Round
Aplagon, based in Helsinki, secured $5.6 million from European Innovation Council Fund and Innovestor.
Transaction Overview
Company Name
Announced On
6/17/2026
Transaction Type
Venture Equity
Amount
$5,600,000
Round
Undisclosed
Investors
European Innovation Council Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support its expansion into a new Phase 2 clinical programme in arteriovenous fistula (AVF) maturation failure in end stage kidney disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Tukholmankatu 8 A
Helsinki, 00290
Finland
Helsinki, 00290
Finland
Phone
Website
Email Address
Overview
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of thromboinflammatory diseases. Aplagon is based on pioneering research on mast cell-derived heparin proteoglycans (HEP-PG) performed by Prof. Riitta Lassila's group at Wihuri Research Institute in Helsinki, Finland.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Aki Prihti
Chief Scientific Officer
Riitta Lassila
Browse more venture capital transactions:
Prev: 6/17/2026: Triveni Bio venture capital transaction
Next: 6/18/2026: Karta venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs